How Aduhelm, an Unproven Alzheimer’s Drug, Got Approved

By | July 20, 2021

[unable to retrieve full-text content]Though some of its own senior officials said there was little evidence of benefit for patients, the F.D.A. nonetheless greenlighted Biogen’s Aduhelm, or aducanumab.
NYT > Health

Read More:  Proteins that predict future dementia, Alzheimer's risk, identified